Videos

Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD. 

Emerging therapies in management of AMD

Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD). 

3 major risk factors of AMD

Ian C. Han, MD, dives into the basics of age-related macular degeneration (AMD) and what patients need to know.

AMD: Learning the basics 

Cheryl Guttman Krader is a contributor to Dermatology Times, Ophthalmology Times, and Urology Times.

Articles

The development of a novel AI-based algorithm aims to improve risk prediction for diabetic eye disease.



From ETDRS to EviRed: Eyeing a new artificial intelligence-based algorithm

Cheryl Guttman is a medical writer based in Deerfield, Ill.

Insights into the pathophysiology of diabetic macular edema are providing a basis for therapeutic interventions.


DME strategies directed by knowledge of mechanisms 

According to investigators at the Wilmer Eye Institute at the Johns Hopkins University School of Medicine conducting experiments in mouse tissues and human cells, by removing a membrane that lines the back of the eye they may be able improve the success rate for regrowing nerve cells damaged by blinding diseases. 

Rift in the retina may pave way for repair of the optic nerve 

Annual Bascom Palmer Eye Institute program will spotlight latest advances in neovascular and exudative ocular disease over 2-day event, February 12-13.

What attendees can expect at the 2021 virtual Angiogenesis meeting

Three sessions cover the range from clinical updates for imaging to emerging therapies for non-exudative AMD.

Angiogenesis 2021: Imaging among the focal points for February 12 agenda

The program features an update on faricimab, plus diabetes, choroiditis, retinitis pigmentosa, and late-breaking reports.

Angiogenesis 2021: February 13 agenda takes on AMD, DME, DR, gene therapy

Rishi P. Singh, MD, highlights various treatment options available for the management of patients with age-related macular degeneration, as well as the status of potential therapies.